Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
0.5255
-0.0199 (-3.65%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Veru Inc. Revenue
Veru Inc. had revenue of $16.89M in the twelve months ending December 31, 2024, up 22.46% year-over-year. In the fiscal year ending September 30, 2024, Veru Inc. had annual revenue of $16.89M with 3.62% growth.
Revenue (ttm)
$16.89M
Revenue Growth
+22.46%
P/S Ratio
4.63
Revenue / Employee
$80,412
Employees
210
Market Cap
78.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 16.89M | 589.46K | 3.62% |
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
VERU News
- 3 days ago - Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit - GlobeNewsWire
- 19 days ago - Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference - GlobeNewsWire
- 2 months ago - Veru Inc (VERU) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress - GlobeNewsWire
- 2 months ago - Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough - Benzinga
- 2 months ago - Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction - GlobeNewsWire
- 3 months ago - Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business - GlobeNewsWire
- 5 months ago - Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders - GlobeNewsWire